Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Nuscale Power Corporation (SMR) Price & Performance

Cassava Sciences IncTrade
Nuscale Power CorporationTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Nuscale Power Corporation — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Nuscale Power Corporation trades at $9.58 (market cap $4.06B). The key difference: Nuscale Power Corporation is far larger — about 85× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

FLNASMR
Market Cap
$47.75M$4.06B
Sector
HealthUtilities
52-Week High
$4.64$53.43
52-Week Low
$0.87$7.59
Enterprise Value
-$34.93M$2.99B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Nuscale Power Corporation

NuScale Power (SMR) trades at $9.58, up 4.36% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net margin of -3,888.7%. Recent news highlights regulatory progress for its small modular reactors and potential from AI data center power demand, though revenue plunged 98.8% year-over-year in Q2 2026.

Outlook hinges on commercial deployment success, with a consensus price target of $10.50 offering 9.6% upside. High execution risk and cash burn are key concerns, but analyst sentiment is 50% buy-rated. Investors face volatility from project timelines versus speculative growth potential in nuclear energy.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Nuscale Power Corporation

NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.

Read more on SMR